Pentixapharm Holding AG (ETR:PTP)

BRIEF

published on 06/09/2026 at 08:09, 3 hours 39 minutes ago

Pentixapharm's [68Ga]Ga-PentixaFor: A Potential Game-Changer in Diagnostics

FDA Approval Pentixapharm [68Ga]Ga-PentixaFor Primary Hyperaldosteronism PET/CT Diagnostics
BRIEF

published on 06/09/2026 at 08:05, 3 hours 44 minutes ago

Pentixapharm Secures FDA IND Clearance for Phase 3 PANDA Study

FDA Clearance Phase 3 Study Cardiovascular Diagnostics Primary Aldosteronism Patient Stratification
PRESS RELEASE

published on 06/09/2026 at 08:04, 3 hours 44 minutes ago

[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
Pentixapharm Holding AG receives FDA approval for Phase III study on [68Ga]Ga-PentixaFor in Primary Aldosteronism, targeting billion-dollar revenue potential in underserved market

FDA Approval Market Potential Primary Aldosteronism Pentixapharm Holding AG [68Ga]Ga-PentixaFor
PRESS RELEASE

published on 06/09/2026 at 08:00, 3 hours 49 minutes ago

Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
Pentixapharm receives FDA clearance for Phase 3 PANDA study of novel cardiovascular diagnostic program targeting resistant hypertension and primary aldosteronism

FDA Clearance Hypertension Cardiovascular Diagnostics Pentixapharm Phase 3 PANDA Study
BRIEF

published on 06/09/2026 at 07:50, 3 hours 59 minutes ago

Pentixapharm Holding AG Advances with FDA Approval and Capital Increase Plan

FDA Approval Capital Increase Primary Aldosteronism PANDA Study BaFin Review
PRESS RELEASE

published on 06/09/2026 at 07:45, 4 hours 4 minutes ago

EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
Pentixapharm Holding AG receives FDA clearance for Phase 3 study, plans capital increase of up to 10 million shares with subscription rights, and faces BaFin financial review

FDA Clearance Capital Increase Phase 3 Study Pentixapharm Holding AG BaFin Review
BRIEF

published on 05/11/2026 at 08:05, 29 days 3 hours ago

Pentixapharm Submits IND to FDA for Phase 3 PANDA Study

Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
PRESS RELEASE

published on 05/11/2026 at 08:00, 29 days 3 hours ago

Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism

Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic
BRIEF

published on 05/07/2026 at 08:05, 1 month 2 days ago

Pentixapharm Q1 2026 Financial and Clinical Development Update

Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
PRESS RELEASE

published on 05/07/2026 at 08:00, 1 month 2 days ago

Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum
Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance

Financial Results Regulatory Pentixapharm Q1 2026 Clinical

1 2 ... 8

Published on 06/09/2026 at 10:15, 1 hour 34 minutes ago

What Waton's New Platform - MoTA Is Designed To Help Users Do
Published on 06/09/2026 at 09:05, 2 hours 44 minutes ago

Uraniumx Reports Anomalous Radioactivity in 300-metre Step-out Holes at Murphy Lake
Published on 06/09/2026 at 02:30, 9 hours 19 minutes ago

Credissential Closes Private Placement
Published on 06/09/2026 at 01:40, 10 hours 9 minutes ago

Linear Minerals Corp Signs Term Sheet for the Sale of Augustus and James Bay Claims
Published on 06/09/2026 at 01:40, 10 hours 9 minutes ago

Three Polaris Projects in Mexico Selected Under the Mixed Development Program

View all ACCESSWIRE

Published on 06/09/2026 at 11:25, 24 minutes ago

Three Prestigious Industry Accolades in One Week: HIZENERGY Solidifies Its C&I Energy Storage Benchmark Status
Published on 06/09/2026 at 10:05, 1 hour 44 minutes ago

Ukrainian Armor advances unmanned ground systems and eyes defense-tech cooperation with Europe
Published on 06/09/2026 at 10:00, 1 hour 49 minutes ago

q.beyond launches “AI Act as a Service”
Published on 06/09/2026 at 10:00, 1 hour 49 minutes ago

WHAT WATON'S NEW PLATFORM - MoTA IS DESIGNED TO HELP USERS DO
Published on 06/09/2026 at 09:35, 2 hours 14 minutes ago

OpenWay collaborates with Visa to help banks launch new payment products at speed and scale

View all EQS

Published on 06/09/2026 at 10:37, 1 hour 12 minutes ago

Guillemot Corporation S.A. | Weekly report share buyback from June 1 to June 5 2026
Published on 06/09/2026 at 07:00, 4 hours 49 minutes ago

New strategic Milestone for Biophytis: Official Establishment of Its Joint Venture in Asia
Published on 06/08/2026 at 17:48, 18 hours 1 minute ago

Reporting on share buyback transactions carried out between June 1 and June 4, 2026
Published on 06/08/2026 at 17:45, 18 hours 4 minutes ago

May 2026
Published on 06/08/2026 at 17:45, 18 hours 4 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News